GlassScriptPhysician profile
Elmer Wilbert Harder
NPI 1215014428
$511.18
in general payments reported to CMS, 2019-2025
12 companies · $60.10 in 2025
The $60.10 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.10 · 2020: $48.40 · 2022: $157 · 2023: $91.32 · 2024: $56.34 · 2025: $60.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $207.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $126.51 | 2019-2025 | |
| Aspira Women'S Health INC | $70.21 | 2022-2024 | Ova1 |
| Coopersurgical, INC. | $57.47 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $48.41 | 2019-2022 | |
| Roche Diagnostics Corporation | $48.40 | 2020 | |
| Exeltis, USA INC. | $47.38 | 2022-2024 | Slynd |
| Hologic Sales and Service, LLC | $34.78 | 2019 | |
| Merck Sharp & Dohme LLC | $18.07 | 2019 | |
| Evofem Biosciences, INC. | $16.33 | 2022 | |
| Astellas Pharma US INC | $15.96 | 2024 | Veozah |
| Minerva Surgical, INC | $13.88 | 2022 | |
| Shield Therapeutics INC | $13.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elmer Harder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.